{"key":"op_491_KR","page":{"url":"https://ru.bookimed.com/clinics/country=republic-of-korea/procedure=kejtruda/","procedure":{"id":491,"slug":"kejtruda","name":"Иммунотерапия Кейтрудой (Пембролизумаб)","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":36,"iso":"KR","name":"Южная Корея"},"currency":"USD","data_date":"2026-10-26"},"pages":{"clinics_url":"https://ru.bookimed.com/clinics/country=republic-of-korea/procedure=kejtruda/","cost_url":"https://ru.bookimed.com/clinics/country=republic-of-korea/procedure=kejtruda/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":4800,"to":7500,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":13500,"to":22000},"uk":{"from":7000,"to":10500},"by_technique":[{"technique":"Pembrolizumab monotherapy","technique_id":"pembrolizumab-monotherapy","price_from":4800,"currency":"USD","source":"estimate","date":"2026-11-17"},{"technique":"Pembrolizumab combined with chemotherapy","technique_id":"pembrolizumab-combined","price_from":6000,"currency":"USD","source":"estimate","date":"2026-11-17"}],"by_city":[{"city":"Сеул","from":4800}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":4500,"to":8000},{"country_iso":"FR","from":4200,"to":7000},{"country_iso":"GB","from":7000,"to":10500},{"country_iso":"US","from":13500,"to":22000},{"country_iso":"IL","from":4800,"to":6800},{"country_iso":"TR","from":2800,"to":7000},{"country_iso":"MX","from":3800,"to":5500},{"country_iso":"DE","from":6000,"to":8100},{"country_iso":"CA","from":6800,"to":9800},{"country_iso":"AE","from":5600,"to":8600},{"country_iso":"TH","from":3600,"to":4600},{"country_iso":"PL","from":4300,"to":5800},{"country_iso":"CZ","from":3600,"to":5300},{"country_iso":"AT","from":5800,"to":8400},{"country_iso":"ES","from":13500,"to":{"status":"missing","reason":"not_collected"}},{"country_iso":"IT","from":4300,"to":6700},{"country_iso":"CN","from":4500,"to":7200},{"country_iso":"AU","from":4800,"to":7400},{"country_iso":"IN","from":2500,"to":5200},{"country_iso":"MY","from":3800,"to":5400},{"country_iso":"VN","from":4300,"to":6200},{"country_iso":"BR","from":4500,"to":7000},{"country_iso":"EG","from":1500,"to":6300}],"base_country":"US","base_is_fallback":false},"savings":{"pct":64,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":3,"items":[{"id":8459,"name":"Myongji Hospital","city":"Goyang","rating":3.6,"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Advanced Regenerative Medicine Implementation Institution (Ministry of Health and Welfare, Republic of Korea)"],"rank":1,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":439,"name":"Gangnam Severance Hospital","city":"Seoul","rating":3.5,"reviews_count":4,"accreditations":["Joint Commission International","Korean Institute for Healthcare Accreditation","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":254,"name":"Severance Hospital","city":"Seoul","rating":4.5,"reviews_count":43,"accreditations":["Joint Commission International","Korean Institute for Healthcare Accreditation","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":{"status":"missing","reason":"not_collected"},"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":328,"slug":"seul","name":"Сеул","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":4800,"profile":{"city_type":"Capital of Republic of Korea","access":["Incheon Airport (ICN), 48 km west of Seoul","Gimpo Airport (GMP), 15 km west of central Seoul"],"sources":["https://en.wikipedia.org/wiki/Seoul","https://en.wikipedia.org/wiki/Incheon_International_Airport","https://en.wikipedia.org/wiki/Gimpo_International_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"horizon":"5 years","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":[]},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":[]},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","revision_rate_pct":null,"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"unit":"percent","horizon":"5 years","population":"Adults with untreated advanced NSCLC, PD-L1 ≥50%, on pembrolizumab monotherapy","evidence_status":"limited"},"techniques":[{"name":"Pembrolizumab monotherapy","suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","recovery":"Outpatient infusion; no downtime in most patients."},{"name":"Pembrolizumab combined with chemotherapy","suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"initial_assessment_documents":["Pathology report with histology","PD-L1, MSI or dMMR test results","Staging CT or PET-CT reports","Prior treatment and surgery summary","Recent blood tests with liver and thyroid function","Oncologist letter on autoimmune disease or ECOG status"],"travel_trips":{"min":2,"max":35,"one_trip_possible":false,"qualifier":"Each 3- or 6-weekly infusion needs a visit; stay 1-3 days per trip. Fewer if a local oncologist continues."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}}},"techniques":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"id":"H1","text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","price_from":4800,"recovery":"Outpatient infusion; no downtime in most patients."},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"id":"H1","text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","price_from":6000,"recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Republic of Korea runs a medical call center where consultants advise overseas patients in several languages around the clock","specialties":[],"source":{"url":"https://www.khidi.or.kr/board?menuId=MENU00807","host":"khidi.or.kr","quote":"Professional consultants provide advices in Korean, English, Japanese, Chinese, Russian and Arabic 24 hours daily.","tier":"government","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2027-05-10","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK travelers can enter Republic of Korea for up to 90 days for short-term business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"You can enter South Korea for up to 90 days for short-term business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US passport holders need a visa for stays in Republic of Korea longer than 90 days and for purposes other than tourism or business, including employment","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"Visa required for all other purposes, including employment, teaching English, and for stays longer than 90 days.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"For a tourist stay of up to 90 days in Republic of Korea, the passport must expire after the date you leave","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"To enter South Korea as a tourist for up to 90 days, your passport must have an ‘expiry date’ after the date you are leaving South Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A valid U.S. passport is required to enter Republic of Korea","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"You must have a valid U.S. passport to enter Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Republic of Korea customs allow small amounts of medication for personal use, if kept in carry-on baggage","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"South Korean customs authorities allow you to bring small amounts of medication for your personal use, if it is kept in carry-on baggage.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"hospital_payment","audience":"all","volatile":false,"text":"In Republic of Korea, health care providers usually require payment before treatment or will not release a patient until hospital bills are paid","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"In most cases, health care providers will require payment in advance of treatment or will not release a patient until hospital bills are paid.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V7","item":"emergency_number","audience":"all","volatile":false,"text":"In Republic of Korea, call 119 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"Call 119 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["azerbaijan","china","dominican-republic","egypt","germany","india","israel","italy","japan","malaysia","mexico","morocco","spain","switzerland","thailand","turkey","ukraine","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.41,"count":47,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Immunotherapy with Keytruda (Pembolizumab) in Republic of Korea typically costs from _op_491_price_from_ to _op_491_price_to_. The total expense depends on the number of cycles and specific cancer type. Patients save around _price_percent_discount_% compared to the US, where this treatment costs _price_compare_US_average_ on average. Fees generally cover the medication, infusion administration, and initial specialist consultations in Seoul.</p>\n\n<ul>\n<li><strong>Hospital tier:</strong> Major university centers in Seoul may charge 15-20% more than regional clinics.</li>\n<li><strong>Infusion cycles:</strong> Costs accrue per session, scaling with the weight-based dosage for each patient.</li>\n<li><strong>Reimbursement status:</strong> National Health Insurance coverage significantly reduces costs for specific oncology indications.</li>\n<li><strong>Combination protocols:</strong> Adding chemotherapy or other targeted agents will increase total treatment expenses.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing JCI-accredited centers like Severance Hospital provides access to world-class multidisciplinary oncology teams. This hospital serves over 1.6 million outpatients annually and maintains high global rankings. While individual sessions start around $3,200 at top centers, the long-term value lies in their advanced digital imaging and AI-driven treatment planning. These technologies help optimize dosage, potentially reducing unnecessary sessions and overall costs.</p>","faq":[{"q":"What are the common side effects of Keytruda (pembrolizumab) treatment reported in Korea?","a":"<p>Common side effects of Keytruda in Korea include dermatologic issues like rashes, endocrine disorders such as hypothyroidism, and gastrointestinal distress. Retrospective data from major Seoul centers indicates that pneumonitis and severe skin reactions like toxic epidermal necrolysis are critical risks requiring immediate monitoring.</p> <ul> <li><strong>Dermatologic reactions:</strong> Skin rashes and itching represent the most frequent side effects reported.</li> <li><strong>Respiratory risks:</strong> Pneumonitis is the most serious adverse event identified in Korean cohorts.</li> <li><strong>Endocrine dysfunction:</strong> Thyroid issues often appear early, typically requiring hormone replacement therapy.</li> <li><strong>Risk factors:</strong> Higher Body Mass Index and treatment cycles increase adverse event risks.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While major centers like Severance Hospital serve millions, their specialization in multidisciplinary care is vital for immunotherapy. Analysis shows that Korean protocols emphasize early intervention for pneumonitis, as it remains the primary cause of severe complications in East Asian patients compared to Western datasets.</p> <p><strong>Patient Consensus:</strong> Patients report that fatigue and thyroid changes often emerge by the second cycle. Many advise tracking symptoms daily and avoiding spicy or fermented foods if gastrointestinal issues like diarrhea begin.</p>"},{"q":"What cancers are currently covered by health insurance for Keytruda in Korea?","a":"<p>South Korea health insurance currently covers Keytruda for 118 indications across 13 cancer types. Key covered areas include lung cancer, melanoma, bladder cancer, Hodgkin lymphoma, and gastric cancer. Recent 2026 expansions added cervical, esophageal, biliary tract, and small intestine cancers to the national reimbursement framework.</p> <ul> <li><strong>Respiratory oncology:</strong> Covers non-small cell lung cancer (NSCLC) with confirmed PD-L1 positive status.</li> <li><strong>Gastrointestinal cancers:</strong> Reimburses gastric, esophageal, colorectal (MSI-H/dMMR), and biliary tract cancer treatments.</li> <li><strong>Rare pathologies:</strong> Includes advanced melanoma and classical Hodgkin lymphoma for refractory disease cases.</li> <li><strong>Biomarker requirements:</strong> Coverage mandates specific markers like PD-L1 expression or MSI-H/dMMR genetic status.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While insurance significantly reduces costs, South Korean reimbursement logic is strictly biomarker-gated. Our data shows clinics like Severance Hospital use advanced digital imaging and EHRs to streamline these approvals. Patients with MSI-H solid tumors often secure coverage faster than those with site-specific indications. Always confirm your PD-L1 status before traveling to avoid unexpected out-of-pocket expenses.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that biopsy-confirmed biomarkers are the only way to avoid high copays. While coverage lags behind the US, the 5% copayment for approved indications makes Korean oncology centers highly accessible.</p>"},{"q":"Is Keytruda approved for early-stage (perioperative) treatment in Korea?","a":"<p>Keytruda is approved for early-stage perioperative treatment in South Korea for non-small cell lung cancer, triple-negative breast cancer, and head and neck squamous cell carcinoma. The Ministry of Food and Drug Safety grants these approvals, though national insurance coverage often lags behind regulatory status for early-stage use.</p> <ul> <li><strong>Approved indications:</strong> Validated for resectable non-small cell lung cancer and high-risk early-stage triple-negative breast cancer.</li> <li><strong>Latest expansion:</strong> Head and neck squamous cell carcinoma received perioperative approval in October 2025.</li> <li><strong>Regulatory authority:</strong> The Ministry of Food and Drug Safety (MFDS) oversees all immunotherapy drug approvals.</li> <li><strong>Insurance gap:</strong> National Health Insurance coverage for many perioperative uses is expected by 2026.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While South Korean clinics like Severance Hospital hold Joint Commission International accreditation, a significant gap exists between drug approval and insurance reimbursement. International patients often access these early-stage treatments as non-reimbursed services, which costs _op_491_price_from_ to _op_491_price_to_ per cycle. This is still approximately _price_percent_discount_% lower than the _price_compare_US_average_ average cost in the United States.</p> <p><strong>Patient Consensus:</strong> Patients report that while regulatory approval exists, accessing Keytruda for early-stage cancer requires navigating complex hospital-specific committees. Many recommend preparing international clinical trial data to support out-of-pocket treatment requests at major Seoul centers.</p>"},{"q":"How is Keytruda administered in Korean hospitals?","a":"<p>Keytruda is administered in South Korea as an intravenous infusion within specialized oncology units at JCI-accredited facilities. The typical 200mg dose takes 30 minutes, followed by 60 minutes of clinical monitoring. Protocol requires pre-infusion bloodwork and corticosteroids to prevent adverse reactions during the three-week cycle.</p> <ul> <li><strong>Administration method:</strong> Delivered via intravenous line in specialized oncology infusion centers.</li> <li><strong>Treatment frequency:</strong> Standard protocols require infusions every 3 or 6 weeks.</li> <li><strong>Session duration:</strong> The infusion lasts 30 minutes with 1 hour of monitoring.</li> <li><strong>Clinical prep:</strong> Mandatory blood tests and premedication manage potential immune-related side effects.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While major centers like Severance Hospital serve millions of patients, international departments offer a streamlined experience. You can often secure same-day consultations and infusions by using these dedicated wings. This bypasses the 2-hour wait times typically found in Korea's public cancer facilities.</p> <p><strong>Patient Consensus:</strong> Patients recommend bringing personal entertainment for the mandatory observation period. Many find the integration of supportive care, such as hydration protocols, helpful for managing fatigue.</p>"}],"h2":[{"text":"Какая цена иммунотерапии кейтрудой (пембролизумаб) в Южной Корее?","kind":"content"},{"text":"Преимущества и гарантии Bookimed","kind":"content"},{"text":"Ваш личный врач-координатор Bookimed","kind":"content"},{"text":"Лучшие клиники по иммунотерапии Кейтрудой (Пембролизумаб) в Южной Корее — 3 проверенных варианта с ценами","kind":"content"},{"text":"Обзор процедуры Иммунотерапия Кейтрудой (Пембролизумаб) в Южной Корее","kind":"content"},{"text":"Получите медицинскую консультацию по иммунотерапии Кейтрудой (Пембролизумаб) в Южной Корее: Выбирайте среди лучших специалистов в этой области","kind":"content"},{"text":"Видеоистории пациентов Bookimed","kind":"content"},{"text":"Отзывы о Bookimed: узнайте о реальном опыте пациентов","kind":"content"},{"text":"Поделитесь этим материалом","kind":"content"},{"text":"Ключевые факты о иммунотерапии Кейтрудой (Пембролизумаб)","kind":"content"},{"text":"FAQ по иммунотерапии Кейтрудой (Пембролизумаб) в Южной Корее","kind":"content"},{"text":"Получить бесплатную консультацию","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}